Table 2.
Clinical outcomes
| Clarithromycin group (N = 27) | Placebo group (N = 31) | Pclarithromycin − Pcontrol | ||
|---|---|---|---|---|
| Clinical outcomes | ||||
| VGPR or better response after VCD induction | No. (%, 95% CI) | 12 (44.4%, 25.5–64.7%) | 16 (51.6%, 33.1–69.8%)a | − 7.2% (− 30.7–17.6%)c |
| VGPR or better response after HDT | No. (%, 95% CI) | 16 (59.3%, 38.8–77.6%) | 23 (74.2%, 55.4–88.1%)a | − 14.9% (− 37.1–8.9%)c |
| Leukapheresis | 106/kg (range) | 8 (2–20) | 8.5 (2–18)b | – |
| Any infection | No. (%, 95% CI) | 16 (59.3%, 38.8–77.6%) | 18 (58.1%, 39.1–75.5%)a | 1.2% (− 23.0–24.9%)c |
VGPR very good partial response, HDT high-dose melphalan with hematopoietic stem cell support
aNot significant (Fisher’s exact test)
bNot significant (Mann–Whitney test)
cPclarithromycin − Pcontrol For response negative numbers indicate lower response in clarithromycin group. For infection positive number indicates higher risk of infection in clarithromycin group